Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer

Inclusion Criteria: * Histologically confirmed metastatic, or recurrent esophageal squamous cell carcinoma * Age \> 18 years * ECOG performance status 0 - 2 * At least one measurable lesion(s) by RECIST 1.1 criteria * Life expectancy ≥ 3 months * At least one cytotoxic chemotherapy regimen (adjuvant chemotherapy will be considered as one regimen if administered within 6 months from the date of study entry) (upto three prior regimens will be allowed) * Prior radiotherapy must be completed 2 weeks before study entry. * Adequate bone marrow function (≥ ANC 1,500/ul, ≥ platelet 100,000/ul, ≥ Hemoglobin 9.0 g/dl) * Adequate renal function (≤ serum creatinine 1.5 mg/dl or CCr ≥ 50 ml/min) * Adequate liver function (≤ serum bilirubin 1.5 mg/dl, ≤ AST/ALT x 3 upper normal limit) * Written informed consent Exclusion Criteria: * Evidence of serious gastrointestinal bleeding * Serious pulmonary conditions/illness (e.g. chronic lung disease with hypoxemia) * Serious metabolic disease such as severe non-compensated diabetes mellitus * History of significant neurologic or psychiatric disorders * Serious uncontrolled intercurrent infections, or other serious uncontrolled concomitant disease * Pregnant or lactating woman